binding affinity News and Research

RSS

Monoclonal antibody HB27 shows potent neutralizing activity against SARS-CoV-2

A new study reports a very promising anti-SARS-CoV-2 monoclonal antibody, HB27, that appears to have two distinct mechanisms of action inhibiting the virus-host cell interaction and subsequent infection.

27 Nov 2020

Phycobilins found to inhibit SARS-CoV-2 enzymes in vitro

Researchers have released an interesting new study that describes the broad-spectrum of antiviral activity that phycobilins can have. Phycobilins, which are bioactive plant compounds, were found to inhibit two coronavirus enzymes.

26 Nov 2020

Researchers recommend antibody cocktail to tackle SARS-CoV-2 mutations

A new study released on the medRxiv* preprint server indicates that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent responsible for the current coronavirus disease 2019 (COVID-19) pandemic – is developing multiple mutations that affect neutralization by antibodies.

24 Nov 2020

Compounds in traditional Chinese medicine herbs may inhibit SARS-CoV-2 infection

Using computational methods, a team of researchers identified three compounds in traditional Chinese medicine that could be used against SARS-CoV-2.

23 Nov 2020

Pomegranate peel extract shows potential as inhibitor of SARS-CoV-2 virus

Researchers led by first author Relja Suručić from the Department of Pharmacognosy, Faculty of Medicine, University of Banja Luka, Banja Luka, Bosnia and Herzegovina, have studied the use of pomegranate peel extracts in preventing infections with SARS-CoV-2.

22 Nov 2020

Several hepatitis C drugs can inhibit crucial protein in SARS-CoV-2

Experiments led by researchers at the Department of Energy's Oak Ridge National Laboratory have determined that several hepatitis C drugs can inhibit the SARS-CoV-2 main protease, a crucial protein enzyme that enables the novel coronavirus to reproduce.

17 Nov 2020

Immune-evading variants can emerge in SARS-CoV-2, researchers warn

An international team of researchers has shown that a mutation within severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent responsible for the coronavirus disease 2019 (COVID-19) – enables the pathogen to evade antibody-mediated immunity while maintaining replication fitness and increasing viral loads.

9 Nov 2020

Rapid generation of divergent synthetic antibodies against SARS-CoV-2 in a cell-free engineering platform

In a groundbreaking bioRxiv paper, a research group from the Massachusetts Institute of Technology (MIT), Harvard University and Howard Hughes Medical Institute in the US engineered antibodies against the receptor-binding domain (RBD) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein by using a novel approach. In doing so, they also identified more than 800 predicted binder families.

3 Nov 2020

SARS-CoV-2 spike D614G variant exhibits enhanced replication and transmissibility

A team of scientists from Switzerland, Germany, and the USA has demonstrated that the S-614G variant can easily bind to the human angiotensin-converting enzyme 2 (ACE2), the cellular gateway of SARS-CoV-2. The variant also showed enhanced replication and transmissibility in animal models.

2 Nov 2020

MD65 IgG-YTE shows powerful post-exposure neutralization of SARS-CoV-2

A recent study published in the preprint server bioRxiv in October 2020 describes a reliable animal model to demonstrate the powerful capacity of human neutralizing mAbs directed against SARS-CoV-2 to prevent viral binding the host cell receptor and thus block infection. This indicates the lifesaving value of mAbs in severe COVID-19.

29 Oct 2020

Scientists compare ACE2 interaction with SARS-CoV-2 across species

Like other pathogenic coronaviruses, SARS-CoV-2 crossed the species barrier to cause human disease. This fact motivated the current study, published on the preprint server bioRxiv* in October 2020, which explores the way coronaviruses engage their host cell receptors in a range of animals.

28 Oct 2020

New peptide derivatives that target the SARS-CoV-2 spike protein

In a new study published in the journal Cellular and Molecular Bioengineering, researchers report peptide derivatives, or peptidomimetics, based on the circle residues involved in the interaction of the spike protein and ACE2.

26 Oct 2020

ACROBiosystems and the Fight Against COVID-19

In this interview, Dr. Yinang Jiang discusses ACROBiosystems and their efforts in the fight against COVID-19 and the search for a vaccine

From ACROBiosystems 23 Oct 2020

Monoclonal Antibodies: Discovery, Characterization and Challenges

In this interview, News-Medical talks to David Apiyo, a senior manager of applications at Sartorius AG, about monoclonal antibody development and characterization.

22 Oct 2020

Integrin b3 and ACE2 linked by short linear motifs enabling endocytosis and autophagy of SARS-CoV-2

A new study by Uppsala University researchers published on the preprint server bioRxiv in October 2020 shows possible links between the angiotensin-converting enzyme 2 (ACE2) host cell receptors for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the entry of viral particles into the cell via endocytosis and autophagy.

12 Oct 2020

New findings could improve investigation of T cell response to COVID-19

Researchers in the United States have made an important discovery about the processing and presentation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral peptides that provides a better understanding of the immune response to coronavirus disease 2019 (COVID-19) and may help facilitate the design of improved vaccines.

5 Oct 2020

Advanced model reveals dynamic motions of SARS-COV-2 spike-shielding glycans

A recent paper published on the preprint server bioRxiv in September 2020 discusses the dynamic interactions of the spike protein glycan shield, which may be of great value in developing therapeutic compounds to fight severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

5 Oct 2020

More evidence Pangolin not intermediary in transmission of SARS-CoV-2 to humans

The team proposed a different model named the ‘circulation model’ to illustrate how SARS-CoV-2-related coronaviruses could have circulated in different species, including humans, before COVID-19 emerged.

4 Oct 2020

New graphical tool to identify potent neutralizing antibodies against SARS-CoV-2

A new study by researchers at the Indian Institute of Science and the University of Queensland and published on the preprint server medRxiv in September 2020 discusses using a novel tool to identify the most effective among currently known anti-SARS-CoV-2 NAbs.

29 Sep 2020

Clover Biopharma's new trimeric subunit vaccine candidate prevents COVID-19 in monkeys

The vaccine candidate produced a high level of neutralizing antibodies in animal models. Rhesus macaques immunized with the vaccine candidate showed reduced viral loads in the lungs. The research is published on the preprint server bioRxiv.

28 Sep 2020